Idol Depletion Protects against Spontaneous Atherosclerosis in a Hamster Model of Familial Hypercholesterolemia
Source : https://www.hindawi.com/journals/omcl/2022/1889632/
Inducible degrader of low-density lipoprotein (LDL) receptor (Idol) is an E3 ubiquitin ligase coded by Idol , the target gene of liver X receptor (LXR), which primarily mediates the ubiquitination...
Relevance: Inducible degrader of low-density lipoprotein (LDL) receptor (Idol) is an E3 ubiquitin ligase coded by Idol, the target gene of liver X receptor (LXR), which primarily mediates the ubiquitination and lysosomal degradation of low-density lipoprotein receptor (LDLR).
New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35625707/
doi: 10.3390/biomedicines10050970. 1 3rd Medical Department with Cardiology and Intensive Care Medicine, Clinic Ottakring (Wilhelminenhospital), Montleartstrasse 37, 1160 Vienna, Austria. 2 Medical School, Sigmund Freud University, 1020 Vienna, Austria. Free...
Relevance: In this review, we summarize evidence for the lipid-modifying properties of these novel agents and their safety profiles, and discuss their potential pleiotropic effects beyond LDL-C reduction (if any) as well as their effects on clinical endpoints as cardiovascular mortality. In addition to a treatment strategy of "the lower, the...
AZD8233 Antisense Oligonucleotide targeting PCSK9 does not prolong QT interval AZD8233 ASO C-QT analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35653229/
AZD8233 is a proprotein convertase subtilisin/kexin type 9 (PCSK9) antisense oligonucleotide under development for treatment of hypercholesterolemia. A prespecified concentration-QT analysis was performed based on data from a single ascending...
Conclusion: As the effect on ΔΔQTcF is below the threshold for regulatory concern (10 ms), it can be concluded that AZD8233 does not induce QTcF prolongation at the high clinical exposure scenario.
Bempedoic acid: a novel oral LDL-cholesterol lowering agent
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123472/
Atherosclerotic Cardiovascular Disease (ASCVD) is the leading cause of morbidity and mortality in the western world. Low-density lipoprotein (LDL)-cholesterol is a major risk factor for premature ASCVD. In addition to...
Relevance: Recently Bempedoic Acid (BA), a first in class ATP-citrate lyase inhibitor was approved for LDL-C reduction based on the CLEAR trials in which BA was superior to Placebo. In addition to lowering LDL-C it also lowers apoB and hsCRP levels. BA appears to be very efficacious in combination with ezetimibe especially in statin intolerant...
Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia
Source : https://www.frontiersin.org/articles/10.3389/fphar.2022.890141/full
Follow-up studies have revealed that during the severe acute respiratory syndrome (SARS) caused by coronavirus SARS-CoV epidemic between 2002 and 2003, a significant proportion of those infected had a deterioration...
Relevance: Follow-up studies have revealed that during the severe acute respiratory syndrome (SARS) caused by coronavirus SARS-CoV epidemic between 2002 and 2003, a significant proportion of those infected had a deterioration in the general health and exercise capacity, especially during the 24 months post-infection.